Compare Flex Ltd (FLEX) vs Summit Therapeutics Inc (SMMT) Price & Performance

Flex LtdTrade

Summit Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Flex Ltd vs Summit Therapeutics Inc — how do they compare? Flex Ltd trades at $120.17 (market cap $42.40B), while Summit Therapeutics Inc trades at $17.6 (market cap $13.71B). The key difference: Flex Ltd is far larger — about 3.1× Summit Therapeutics Inc's market cap, and Flex Ltd is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Flex Ltd for 4 Days and Summit Therapeutics Inc for 16 Days on average.

	FLEX	SMMT
Market Cap	$42.40B	$13.71B
Volume	2,642,359	6,173,057
Sector	Technology	Health
52-Week High	$162.07	$26.38
52-Week Low	$54.51	$12.43
Typical Hold Time	4 Days	16 Days
Enterprise Value	$45.49B	$13.04B

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Flex Ltd

No Aura AI signal available yet.

Summit Therapeutics Inc

Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.

The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

FLEX

Flex to report Q2 FY2027 earnings on Oct 28 with a live webcast and conference call.PRNewsWire · 2 days agoNeutral Flex's AI data center spin-off Axiom valued at $37.5B with $2B investment from General Catalyst.24/7 Wall Street · 3 days agoBullish Flex secures $2B investment to spin off Axiom as independent AI infrastructure firm by early 2027PRNewsWire · 4 days agoBullish View details →

SMMT

AstraZeneca invests $2B in Summit Therapeutics to advance next-gen cancer drug ivonescimab.CNBC · 4 days agoBullish View details →

About Flex Ltd

Flex provides design, engineering, manufacturing, supply chain, and logistics services for technology products. It serves industries including cloud, data centers, communications, automotive, healthcare, and industrials.

About Summit Therapeutics Inc

Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.